

Date Collected: 07/02/2024

Date Received: 07/02/2024

Date Reported: 07/17/2024

Fasting: Yes

Ordered Items: STATUS REPORT; CBC with Diff, Platelet, NLR; Comp. Metabolic Panel (14); Lipid Panel With LDL/HDL Ratio; Testosterone, F Eqlib+T LC/MS; Hemoglobin A1c; Thyroxine (T4) Free, Direct; DHEA-Sulfate; TSH; Prolactin; Prostate-Specific Ag; IGF-1; Reverse T3, Serum; C-Reactive Protein, Cardiac; Estradiol, Sensitive; Insulin; Triiodothyronine (T3), Free; Sex Horm Binding Glob, Serum; Apolipoprotein B; Venipuncture

Date Collected: 07/02/2024

STATUS REPORT

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|-----------------------------|-------------------------|--------------------------|-------|--------------------|
| STATUS REPORT ⁰¹ | Will Follow | | | |

CBC with Diff, Platelet, NLR

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|---|-------------------------|--------------------------|----------|--------------------|
| WBC ⁰² | 4.3 | | x10E3/uL | 3.4-10.8 |
| RBC ⁰² | 5.51 | | x10E6/uL | 4.14-5.80 |
| Hemoglobin ⁰² | 16.7 | | g/dL | 13.0-17.7 |
| ▲ Hematocrit ⁰² | 51.5High | | % | 37.5-51.0 |
| MCV ⁰² | 94 | | fL | 79-97 |
| MCH ⁰² | 30.3 | | pg | 26.6-33.0 |
| MCHC ⁰² | 32.4 | | g/dL | 31.5-35.7 |
| RDW ⁰² | 12.5 | | % | 11.6-15.4 |
| Platelets ⁰² | 210 | | x10E3/uL | 150-450 |
| Neutrophils ⁰² | 44 | | % | Not Estab. |
| Lymphs ⁰² | 39 | | % | Not Estab. |
| Monocytes ⁰² | 11 | | % | Not Estab. |
| Eos ⁰² | 5 | | % | Not Estab. |
| Basos ⁰² | 1 | | % | Not Estab. |
| Neutrophils (Absolute) ⁰² | 1.9 | | x10E3/uL | 1.4-7.0 |
| Lymphs (Absolute) ⁰² | 1.7 | | x10E3/uL | 0.7-3.1 |
| Neut/Lymph Ratio | 1.1 | | ratio | 0.0-2.9 |
| Published COVID-19 studies suggest: Low likelihood of severe COVID-19 disease progression0.0-2.9 High likelihood of severe COVID-19 disease progression>4.9 | | | | |
| Monocytes(Absolute) ⁰² | 0.5 | | x10E3/uL | 0.1-0.9 |
| Eos (Absolute) ⁰² | 0.2 | | x10E3/uL | 0.0-0.4 |
| Baso (Absolute) ⁰² | 0.1 | | x10E3/uL | 0.0-0.2 |
| Immature Granulocytes ⁰² | 0 | | % | Not Estab. |
| Immature Grans (Abs) ⁰² | 0.0 | | x10E3/uL | 0.0-0.1 |

Comp. Metabolic Panel (14)

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|-----------------------|-------------------------|--------------------------|-------|--------------------|
| Glucose ⁰² | 85 | | mg/dL | 70-99 |
| BUN ⁰² | 17 | | mg/dL | 6-20 |

Date Collected: 07/02/2024

Comp. Metabolic Panel (14) (Cont.)

| | | | | |
|-------------------------------------|------|-----|-------------|-----------|
| Creatinine ⁰² | 1.04 | | mg/dL | 0.76-1.27 |
| eGFR | 100 | | mL/min/1.73 | >59 |
| BUN/Creatinine Ratio | 16 | | | 9-20 |
| Sodium ⁰² | 138 | | mmol/L | 134-144 |
| Potassium ⁰² | 4.1 | | mmol/L | 3.5-5.2 |
| Chloride ⁰² | 100 | | mmol/L | 96-106 |
| Carbon Dioxide, Total ⁰² | 24 | | mmol/L | 20-29 |
| Calcium ⁰² | 8.9 | | mg/dL | 8.7-10.2 |
| Protein, Total ⁰² | 6.6 | | g/dL | 6.0-8.5 |
| ▼ Albumin ⁰² | 4.1 | Low | g/dL | 4.3-5.2 |
| Globulin, Total | 2.5 | | g/dL | 1.5-4.5 |
| Bilirubin, Total ⁰² | 0.6 | | mg/dL | 0.0-1.2 |
| Alkaline Phosphatase ⁰² | 51 | | IU/L | 44-121 |
| AST (SGOT) ⁰² | 33 | | IU/L | 0-40 |
| ALT (SGPT) ⁰² | 29 | | IU/L | 0-44 |

Lipid Panel With LDL/HDL Ratio

| Test | Current Result and Flag | | Previous Result and Date | Units | Reference Interval |
|----------------------------------|-------------------------|-----|--------------------------|-------|--------------------|
| Cholesterol, Total ⁰² | 136 | | | mg/dL | 100-199 |
| Triglycerides ⁰² | 77 | | | mg/dL | 0-149 |
| ▼ HDL Cholesterol ⁰² | 39 | Low | | mg/dL | >39 |
| VLDL Cholesterol Cal | 15 | | | mg/dL | 5-40 |
| LDL Chol Calc (NIH) | 82 | | | mg/dL | 0-99 |
| LDL/HDL Ratio | 2.1 | | | ratio | 0.0-3.6 |
| Please Note: ⁰² | | | | | |
| LDL/HDL Ratio | | | | | |
| Men Women | | | | | |
| 1/2 Avg.Risk 1.0 1.5 | | | | | |
| Avg.Risk 3.6 3.2 | | | | | |
| 2X Avg.Risk 6.2 5.0 | | | | | |
| 3X Avg.Risk 8.0 6.1 | | | | | |

Testosterone, F Eqlib+T LC/MS

| Test | Current Result and Flag | | Previous Result and Date | Units | Reference Interval |
|--|-------------------------|------|--------------------------|-------|--------------------|
| ▲ Testosterone, Total, LC/MS ^{A, 01} | 1344.1 | High | | ng/dL | 264.0-916.0 |
| This LabCorp LC/MS-MS method is currently certified by the CDC Hormone Standardization Program (HoSt). Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103. | | | | | |
| Testosterone, Free | Will Follow | | | | |
| % Free Testosterone ⁰¹ | | | | % | 1.50-4.20 |
| Specimen has been received and initial testing has been performed. However, additional testing is required to verify initial results. Final result to follow. | | | | | |

Date Collected: 07/02/2024

Hemoglobin A1c

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|------------------------------|---|--------------------------|-------|--------------------|
| Hemoglobin A1c ⁰² | 5.0 | | % | 4.8-5.6 |
| Please Note: ⁰² | Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0 | | | |

Thyroxine (T4) Free, Direct

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|-------------------------------|-------------------------|--------------------------|-------|--------------------|
| T4,Free(Direct) ⁰² | 1.17 | | ng/dL | 0.82-1.77 |

DHEA-Sulfate

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|------------------------------|-------------------------|--------------------------|-------|--------------------|
| ▲ DHEA-Sulfate ⁰² | 646.0 High | | ug/dL | 138.5-475.2 |

TSH

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|-------------------|-------------------------|--------------------------|--------|--------------------|
| TSH ⁰² | 0.816 | | uIU/mL | 0.450-4.500 |

Prolactin

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|-------------------------|-------------------------|--------------------------|-------|--------------------|
| Prolactin ⁰² | 11.8 | | ng/mL | 3.6-31.5 |

Prostate-Specific Ag

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|--|-------------------------|--------------------------|-------|--------------------|
| Prostate Specific Ag ⁰² | 0.6 | | ng/mL | 0.0-4.0 |
| Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. | | | | |

IGF-1

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|--|-------------------------|--------------------------|-------|--------------------|
| Insulin-Like Growth Factor I ⁰¹ | 254 | | ng/mL | 101-307 |

Reverse T3, Serum

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|---|-------------------------|--------------------------|-------|--------------------|
| Reverse T3, Serum ⁰³ | 21.9 | | ng/dL | |
| This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. | | | | |

Date Collected: 07/02/2024

Reverse T3, Serum (Cont.)

Reference Range :
>15y: 9.2 - 24.1

C-Reactive Protein, Cardiac

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|---|-------------------------|--------------------------|-------------|--------------------|
| C-Reactive Protein, Cardiac ⁰² | 0.81 | | mg/L | 0.00-3.00 |
| Relative Risk for Future Cardiovascular Event | | | | |
| Low | | | <1.00 | |
| Average | | | 1.00 - 3.00 | |
| High | | | >3.00 | |

Estradiol, Sensitive

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|---|-------------------------|--------------------------|-------|--------------------|
| ▲ Estradiol, Sensitive ^{A, 01} | 50.3 High | | pg/mL | 8.0-35.0 |
| Methodology: Liquid chromatography tandem mass spectrometry(LC/MS/MS) | | | | |

Insulin

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|-----------------------|-------------------------|--------------------------|--------|--------------------|
| Insulin ⁰² | 4.4 | | uIU/mL | 2.6-24.9 |

Triiodothyronine (T3), Free

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|---|-------------------------|--------------------------|-------|--------------------|
| Triiodothyronine (T3), Free ⁰² | 4.2 | | pg/mL | 2.0-4.4 |

Sex Horm Binding Glob, Serum

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|--|-------------------------|--------------------------|--------|--------------------|
| Sex Horm Binding Glob, Serum ⁰² | 28.5 | | nmol/L | 16.5-55.9 |

Apolipoprotein B

| Test | Current Result and Flag | Previous Result and Date | Units | Reference Interval |
|--------------------------------|-------------------------|----------------------------------|-------|--------------------|
| Apolipoprotein B ⁰⁴ | 68 | | mg/dL | <90 |
| Desirable < 90 | | | | |
| Borderline High 90 - 99 | | | | |
| High 100 - 130 | | | | |
| Very High >130 | | | | |
| ----- | | | | |
| ASCVD RISK CATEGORY | | THERAPEUTIC TARGET APO B (mg/dL) | | |
| Very High Risk | | <80 (if extreme risk <70) | | |
| High Risk | | <90 | | |
| Moderate Risk | | <90 | | |

Disclaimer
The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

Icon Legend
▲ Out of Reference Range ■ Critical or Alert

Comments
A: This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Performing Labs
01: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD
02: HD - LabCorp Houston, 7207 North Gessner, Houston, TX 77040-3143 Dir: Kyle Eskue, MD
03: ES - Esoterix Inc, 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358 Dir: Brian Poirier, MD
04: DA - Labcorp Dallas, 7777 Forest Ln Bldg C350, Dallas, TX 75230-2544 Dir: CN Etufugh, MD
For Inquiries, the physician may contact Branch: 800-762-4344 Lab: 713-856-8288

| Patient Details | Physician Details | Specimen Details |
|--|--|---------------------------------------|
| Anderton, Tyler | D FINK | Specimen ID: 184-363-4427-0 |
| 4004 BANISTER LN UNIT 312, AUSTIN, TX, 78704 | Marek Health | Control ID: 52114082 |
| | 35 W Huron St Ste 1000, Pontiac, MI, 48342 | Alternate Control Number: 52114082 |
| Phone: | Phone: 877-572-2582 | Date Collected: 07/02/2024 1010 Local |
| Date of Birth: 05/26/1995 | Account Number: 21025370 | Date Received: 07/02/2024 0000 ET |
| Age: 29 | Physician ID: 1891814521 | Date Entered: 07/02/2024 1132 ET |
| Sex: Male | NPI: 1891814521 | Date Reported: 07/17/2024 1435 ET |
| Patient ID: MH59255 | | |
| Alternate Patient ID: MH59255 | | |